menu
    • menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Loxo Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Loxo Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"VEGFR 1\/3","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Selpercatinib

    Menu

    Selpercatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Retevmo lands new accelerated approval for pediatric cancers

                            Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with CNS activity, which is investigated for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer.

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 29, 2024

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chugai Pharmaceutical

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chugai Gets Approval for FoundationOne CDx as Companion Diagnostic for RET Inhibitor

                            Details : Retevmo (selpercatinib) is an oral RET receptor tyrosine kinase inhibitor, small molecule drug candidate which is indicated for the treatment of RET fusion-positive solid tumors.

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 29, 2024

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multiki...

                            Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is investigated for the treatment of advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid canc...

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2023

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survi...

                            Details : Retevmo (selpercatinib) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity, which is used for the treatment of Adults with Newly-Diagnosed Advanced or Metastatic RET fusion-positive non-small Cell lung cancer...

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2023

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innovent Biologics

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-Driven Lung and Thyroid Cancers

                            Details : Selpercatinib is selective and potent RET kinase inhibitor demonstrated potent and durable antitumor activity with favorable safety profile in patients with advanced or metastatic RET fusion-positive NSCLC, metastatic RET-mutant MTC and advanced RET fusi...

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 10, 2022

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Eli Lilly

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or M...

                            Details : In the LIBRETTO-001 trial, Retevmo (selpercatinib) demonstrated clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon and other cancers in need of new treatment option...

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung C...

                            Details : Twenty-six patients had measurable central nervous system metastases at baseline and treatment with Retevmo resulted in a CNS ORR of 84.6%, with 22 patients having a confirmed best response of complete response or partial response.

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2022

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Loxo Oncology Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly Presents New Data on Retevmo in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 ...

                            Details : First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.

                            Brand Name : Retevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2021

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Loxo Oncology Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly's Cancer Drug Retsevmo Gets UK Approval for Multiple Indications

                            Details : The agency approved selpercatinib for the treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

                            Brand Name : Retsevmo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 10, 2021

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy

                            Details : Retevmo™ (selpercatinib) has been approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 08, 2020

                            Lead Product(s) : Selpercatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth